Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Pearson, ADJ, Zwaan, C.M., Kolb, EA, Karres, D, Guillot, J, Kim, SY, Marshall, L, Tasian, SK, Smith, M, Cooper, T, Adamson, PC, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, DV, Fogelstrand, L, Fraenkel, PG, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, JH, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G, Vassal, G

Publikováno v: European journal of cancer
Pearson, A D J, Zwaan, C M, Kolb, E A, Karres, D, Guillot, J, Kim, S Y, Marshall, L, Tasian, S K, Smith, M, Cooper, T, Adamson, P C, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, D V, Fogelstrand, L, Fraenkel, P G, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, J H, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G & Vassal, G 2020, ' Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration ', European Journal of Cancer, vol. 136, pp. 116-129 . https://doi.org/10.1016/j.ejca.2020.04.038
European Journal of Cancer, 136, 116-129. Pergamon
European Journal of Cancer, 136, 116-129. Elsevier Ltd.

Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ea901e797ad2961db6c39007f2797adc
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85087974955

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.

Autor: Bonnevaux H; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Guerif S; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Albrecht J; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Jouannot E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., De Gallier T; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Beil C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Lange C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Leuschner WD; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Schneider M; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Lemoine C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Caron A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Amara C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Barrière C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Siavellis J; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France., Bardet V; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France., Luna E; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Agrawal P; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Drake DR; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Rao E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Wonerow P; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Carrez C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Blanc V; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Hsu K; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Wiederschain D; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Fraenkel PG; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Virone-Oddos A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Aug 31; Vol. 10 (1), pp. 1945803. Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).

Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis.

Autor: Poluben L; National Research Center for Radiation Medicine, Kyiv 02000, Ukraine., Bryke CR; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA., Hsu Y; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA., Shumeiko O; O.O. Bogomolets National Medical University, Kyiv 01601, Ukraine., Neumerzhitska L; National Research Center for Radiation Medicine, Kyiv 02000, Ukraine., Klimuk B; National Research Center for Radiation Medicine, Kyiv 02000, Ukraine., Rybchenko L; National Research Center for Radiation Medicine, Kyiv 02000, Ukraine., Klymenko S; National Research Center for Radiation Medicine, Kyiv 02000, Ukraine., Balk SP; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA., Fraenkel PG; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA.

Publikováno v: Experimental oncology [Exp Oncol] 2019 Mar; Vol. 41 (1), pp. 53-56.

Nicotinamide N-methyltransferase expression decreases in iron overload, exacerbating toxicity in mouse hepatocytes.

Autor: Koppe T; Division of Hematology/Oncology.; Cancer Research Institute, Beth Israel Deaconess Medical Center Boston MA.; Department of Medicine Harvard Medical School Boston MA., Patchen B; Division of Hematology/Oncology.; Cancer Research Institute, Beth Israel Deaconess Medical Center Boston MA.; Department of Medicine Harvard Medical School Boston MA., Cheng A; Division of Hematology/Oncology.; Cancer Research Institute, Beth Israel Deaconess Medical Center Boston MA.; Department of Medicine Harvard Medical School Boston MA., Bhasin M; Department of Medicine Harvard Medical School Boston MA.; Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center Boston MA., Vulpe C; Department of Physiological Sciences University of Florida Gainesville FL., Schwartz RE; Division of Gastroenterology and Hepatology, Weill Cornell Medical School New York NY., Moreno-Navarrete JM; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona Hospital de Girona Dr. Josep Trueta and Universitat de Girona Girona Spain.; CIBER Fisopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III Madrid Spain., Fernandez-Real JM; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona Hospital de Girona Dr. Josep Trueta and Universitat de Girona Girona Spain.; CIBER Fisopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III Madrid Spain., Pissios P; Division of Endocrinology, Beth Israel Deaconess Medical Center Boston MA., Fraenkel PG; Division of Hematology/Oncology.; Cancer Research Institute, Beth Israel Deaconess Medical Center Boston MA.; Department of Medicine Harvard Medical School Boston MA.

Publikováno v: Hepatology communications [Hepatol Commun] 2017 Sep 11; Vol. 1 (8), pp. 803-815. Date of Electronic Publication: 2017 Sep 11 (Print Publication: 2017).